Skip to search formSkip to main contentSkip to account menu

Myeloid Leukemia

Known as: LEUKEMIA, GRANULOCYTIC, MALIGNANT, Myelocytic Leukemias, Unspecified myeloid leukemia 
A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are… 
National Institutes of Health

Related topics

Related topics

48 relations
ABL2 geneABL2 wt AlleleANXA8 geneAcute Promyelocytic Leukemia
Expand

Narrower (8)

Acute myelomonocytic leukemiaEosinophilic leukemiaGranulocytic SarcomaLeukemia, Myelocytic, Acute
Expand

Broader (3)

Neoplasm, uncertain whether benign or malignantNeoplasmsleukemia

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
BACKGROUND Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next… 
Highly Cited
2013
Highly Cited
2013
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
BACKGROUND Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships… 
Review
2010
Review
2010
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment… 
Highly Cited
2009
Highly Cited
2009
Recurring mutations found by sequencing an acute myeloid leukemia genome.
BACKGROUND The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not… 
Highly Cited
2006
Highly Cited
2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this… 
Highly Cited
2003
Highly Cited
2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic… 
Review
2002
Review
2002
Acute myeloid leukemia.
In this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid… 
Highly Cited
2001
Highly Cited
2001
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine… 
Highly Cited
2001
Highly Cited
2001
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
BACKGROUND BCR-ABL, a constitutively activated tyrosine kinase, is the product of the Philadelphia chromosome. This enzyme is… 
Highly Cited
1997
Highly Cited
1997
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License